OmniAb, Inc. (NASDAQ:OABI) Shares Bought by Barclays PLC

Barclays PLC grew its holdings in shares of OmniAb, Inc. (NASDAQ:OABI) by 321.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 143,215 shares of the company’s stock after purchasing an additional 109,236 shares during the period. Barclays PLC owned approximately 0.10% of OmniAb worth $606,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Dimensional Fund Advisors LP increased its stake in OmniAb by 6.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company’s stock valued at $11,296,000 after buying an additional 194,835 shares during the period. Rice Hall James & Associates LLC increased its stake in shares of OmniAb by 6.4% during the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock valued at $11,515,000 after acquiring an additional 163,038 shares during the period. State Street Corp raised its holdings in OmniAb by 1.7% during the third quarter. State Street Corp now owns 2,031,676 shares of the company’s stock worth $8,594,000 after purchasing an additional 34,654 shares in the last quarter. Murchinson Ltd. acquired a new stake in OmniAb in the third quarter worth approximately $4,230,000. Finally, Woodstock Corp lifted its position in OmniAb by 5.6% in the third quarter. Woodstock Corp now owns 792,853 shares of the company’s stock worth $3,354,000 after purchasing an additional 42,310 shares during the period. 72.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently commented on OABI. Benchmark reissued a “buy” rating and issued a $8.00 price objective on shares of OmniAb in a research note on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of OmniAb in a research report on Thursday, November 14th.

OmniAb Stock Performance

NASDAQ OABI opened at $3.18 on Friday. OmniAb, Inc. has a 1 year low of $3.16 and a 1 year high of $6.55. The business’s fifty day moving average is $3.80 and its two-hundred day moving average is $4.08. The stock has a market capitalization of $449.08 million, a P/E ratio of -5.13 and a beta of -0.10.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.